Agilent Technologies and SomaLogic have signed a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic’s novel SOMAscan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development.
SomaLogic’s SOMAscan assay solves a protein measurement challenge using a DNA measurement solution, enabling the accurate measurement of an individual’s protein makeup with unequalled sensitivity and dynamic range. The customized Agilent microarray, which is based on SomaLogic’s specifications, is incorporated into the SOMAscan assay which is used to detect and measure 5,000 proteins accurately and reproducibly from a small volume of a biological sample.
“Agilent’s microarray platform has demonstrated superiority for measurement of DNA and RNA at scale and it is exciting to see how SomaLogic is creatively applying this capability to measure thousands of proteins in a single assay,” said Sam Raha, president of Agilent’s Diagnostics and Genomics Group.
Roy Smythe, CEO of SomaLogic added, “Agilent custom microarrays have been a critical part of our success to date, and as we now move into health, wellness and disease-monitoring applications for our technology they continue to be extremely high quality and scalable solution.”
Further details of the agreement were not disclosed.